Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-latent TGFb1 monoclonal antibody RO7496353

A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, anti-latent TGFb1 monoclonal antibody RO7496353 targets, binds to, and inhibits the activation of latent TGFb1 complexes, thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the predominant isoform in many tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-latent TGF-beta 1 monoclonal antibody RO7496353
anti-latent TGF-beta1 monoclonal antibody RG6440
anti-latent TGF-beta1 monoclonal antibody RO7496353
anti-latent TGF-beta1 monoclonal antibody SOF10
Code name:RG 6440
RG-6440
RG6440
RO 7496353
RO-7496353
RO7496353
SOF 10
SOF-10
SOF10
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search